$PTCT Q3 '26 Earnings Results & Recap
• Reported GAAP EPS of -$0.62 down -410.00% YoY
• Reported revenue of $357.81M up 69.57% YoY
• PTC Therapeutics increased full-year 2026 expected total revenue to $1.29 to $1.32B and raised product revenue guidance to $960 to $990M; GAAP expense guidance remains $775 to $815M.